Marinus Pharmaceuticals Inc (NASDAQ:MRNS)’s traded shares stood at 0.63 million during the latest session, with the company’s beta value hitting 1.20. At the last check today, the stock’s price was $0.27, to imply an increase of 4.47% or $0.01 in intraday trading. The MRNS share’s 52-week high remains $11.26, putting it -4070.37% down since that peak but still an impressive 18.52% since price per share fell to its 52-week low of $0.22. The company has a valuation of $14.82M, with an average of 1.21 million shares in intraday trading volume over the past 10 days and average of 2.63 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Marinus Pharmaceuticals Inc (MRNS), translating to a mean rating of 2.56. Of 2 analyst(s) looking at the stock, 0 analyst(s) give MRNS a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 1 recommend it as a Buy.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Marinus Pharmaceuticals Inc (NASDAQ:MRNS) trade information
After registering a 4.47% upside in the latest session, Marinus Pharmaceuticals Inc (MRNS) has traded red over the past five days. The 5-day price performance for the stock is 10.30%, and -17.02% over 30 days. With these gigs, the year-to-date price performance is -97.53%. Short interest in Marinus Pharmaceuticals Inc (NASDAQ:MRNS) saw shorts transact 5.66 million shares and set a 1.09 days time to cover.
The extremes give us $6 and $6 for target low and target high price respectively. As such, MRNS has been trading -2122.22% off suggested target high and -2122.22% from its likely low.
Marinus Pharmaceuticals Inc (MRNS) estimates and forecasts
Looking at statistics comparing Marinus Pharmaceuticals Inc share performance against respective industry, we note that the company has outperformed competitors. Marinus Pharmaceuticals Inc (MRNS) shares are -78.15% down over the last 6 months, with its year-to-date growth rate higher than industry average at 22.81% against 16.40%.
MRNS Dividends
Marinus Pharmaceuticals Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Marinus Pharmaceuticals Inc (NASDAQ:MRNS)’s Major holders
Marinus Pharmaceuticals Inc insiders hold 10.94% of total outstanding shares, with institutional holders owning 83.04% of the shares at 93.24% float percentage. In total, 83.04% institutions holds shares in the company, led by TANG CAPITAL MANAGEMENT LLC. As of 2024-06-30, the company held over 4.8 million shares (or 8.443% of shares), all amounting to roughly $5.62 million.
The next major institution holding the largest number of shares is SOFINNOVA INVESTMENTS, INC. with 4.15 million shares, or about 7.3025% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $4.86 million.
We also have Vanguard Total Stock Market Index Fund and abrdn Healthcare Investors as the top two Mutual Funds with the largest holdings of the Marinus Pharmaceuticals Inc (MRNS) shares. Going by data provided on Sep 30, 2024, Vanguard Total Stock Market Index Fund holds roughly 1.73 shares. This is just over 3.14% of the total shares, with a market valuation of $0.47 million. Data from the same date shows that the other fund manager holds a little less at 1.53, or 2.78% of the shares, all valued at about 0.42 million.
